Meta AnalysisID 2022
磷酸肌酸对接受冠状动脉旁路移植术患者的影响：一项系统评价Meta分析
CRD42023391528
To systemically evaluate the effects of phosphocreatine on patients undergoing coronary artery bypass
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 2022
- Evidence Id
- 10580
- Core Evidence Id
- 10580
- Source Meta Analysis Id
- 1965
- Herb2 Meta Analysis Id
- HBMA001965
- Crd Id
- CRD42023391528
- Title
- The effects of phosphocreatine on patients undergoing coronary artery bypass: a systemic review meta-analysis
- Review Question
- To systemically evaluate the effects of phosphocreatine on patients undergoing coronary artery bypass
- Study Type Included
- We included all RCTs comparing phosphocreatine with control in CABG patients
- Condition Being Studied
- Perioperative care
- Participant
- We included all clinical trials comparing phosphocreatine vs control(placebo/blank/other agents) in patients undergoing CABG. Exclusion criteria included (1)studies published as review, case report or abstract; (2)animal or cell studies; (3)duplicate publications; (4)studies lacking information about outcomes of interest. The two authors independently reviewed the titles and abstracts of all identified studies for eligibility, excluding obviously ineligible ones. P=patients undergoing CABG
- Animal
- Human Disease Modelled
- Intervention
- We included all clinical trials comparing phosphocreatine vs control(placebo/blank/other agents) in patients undergoing CABG. Exclusion criteria included (1)studies published as review, case report or abstract; (2)animal or cell studies; (3)duplicate publications; (4)studies lacking information about outcomes of interest. The two authors independently reviewed the titles and abstracts of all identified studies for eligibility, excluding obviously ineligible ones. I=phosphocreatine
- Comparator Control
- We included all clinical trials comparing phosphocreatine vs control(placebo/blank/other agents) in patients undergoing CABG. Exclusion criteria included (1)studies published as review, case report or abstract; (2)animal or cell studies; (3)duplicate publications; (4)studies lacking information about outcomes of interest. The two authors independently reviewed the titles and abstracts of all identified studies for eligibility, excluding obviously ineligible ones. C=placebo/blank/other agents
- Main Outcome
- Myocardial inury biomarkers levels(e.g, cTn, LDH，CK)
- Outcome Measure
- Additional Outcome
- Perioperative hemodynamics(blood pressure, heart rate..)，the incidences of mortality and morbities, postoperative recovery.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- Cardiopulmonary Bypass; Coronary Artery Bypass; Humans; Patients; Phosphocreatine
- Contact
- Yuntai Yao [email protected]
- Organisational Affiliation
- Anesthesia Center, Fuwai Hospital
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-01-13
- Registration Date
- 2023-01-24
- Anticipated Start Date
- 2023-07-01
- Anticipated Completion Date
- 2024-03-31
- Title Cn
- 磷酸肌酸对接受冠状动脉旁路移植术患者的影响：一项系统评价Meta分析
- Title En
- The effects of phosphocreatine on patients undergoing coronary artery bypass: a systemic review meta-analysis
- Bilingual Status
- complete